{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:20Z","timestamp":1791287600431,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Propionic aciduria (PA) and methylmalonic aciduria (MMA) are rare inherited metabolic disorders marked by recurrent metabolic decompensation and hyperammonaemia, resulting in neurological morbidity, chronic complications, and substantial healthcare burden. Although carglumic acid (Carbaglu\u00ae) is established for acute hyperammonaemic crises, evidence for its long-term use is limited. This study reports the 18-month interim analysis of PROTECT, a large prospective observational study evaluating chronic Carbaglu\u00ae therapy in PA and MMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PROTECT is a prospective, longitudinal, observational study conducted across 34 centres in seven European countries. Patients with PA or MMA receiving long-term Carbaglu\u00ae for at least six months were eligible. Clinical data were extracted from medical records and analysed descriptively. Annualised pre- and post-treatment comparisons were performed in patients with at least six months of life without long-term Carbaglu\u00ae prior to initiation. Outcomes included metabolic decompensation events, ammonia control, healthcare utilisation, and growth parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-eight patients were included in this interim analysis. Among 39 evaluable patients, long-term Carbaglu\u00ae treatment was associated with reduced annualised metabolic decompensation events, including hyperammonaemic episodes. Mean peak ammonia levels during decompensations and background ammonia concentrations were significantly lower following treatment initiation. Healthcare utilisation decreased substantially, with significant reductions in inpatient admissions, inpatient days, and emergency room visits. Growth parameters remained stable in patients initiating treatment later in life, while patients treated from birth demonstrated sustained metabolic stability and favourable growth profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite heterogeneity and limitations inherent to real-world observational data, these findings indicate clinically meaningful improvements in metabolic control and healthcare burden with long-term Carbaglu\u00ae therapy. Reductions in both acute and background ammonia exposure suggest potential cumulative neuroprotective benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This 18-month interim analysis supports Carbaglu\u00ae as a beneficial long-term treatment option for patients with PA and MMA, with particular promise when initiated early in life. Ongoing follow-up will further clarify long-term outcomes and inform optimisation of chronic management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial statement<\/jats:title>\n                    <jats:p>Findings based on clinical trial NCT04176523 titled the PRospective Observational study of long-TErm Carbaglu\u00ae for the Treatment of PA &amp; MMA (PROTECT), registered retrospectively at ClinicalTrials.gov on 25th November 2019, available at https:\/\/clinicaltrials.gov\/study\/NCT04176523.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04522-z","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:15:46Z","timestamp":1785773746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world experience of carglumic acid for methylmalonic and propionic acidurias: the second interim analysis of the multicentre observational PROTECT study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-4876","authenticated-orcid":false,"given":"Sufin","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Dougherty-de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Ca\u00f1edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinziana","family":"Stanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Delcroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Boutoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"3","key":"4522_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/jimd.12617","volume":"46","author":"PE Head","year":"2023","unstructured":"Head PE, Meier JL, Venditti CP. New insights into the pathophysiology of methylmalonic acidemia. J Inherit Metab Dis. 2023;46(3):436\u201349. https:\/\/doi.org\/10.1002\/jimd.12617.","journal-title":"J Inherit Metab Dis"},{"key":"4522_CR2","doi-asserted-by":"publisher","first-page":"108501","DOI":"10.1016\/j.pharmthera.2023.108501","volume":"249","author":"H Marchuk","year":"2023","unstructured":"Marchuk H, Wang Y, Ladd ZA, et al. Pathophysiological mechanisms of complications associated with propionic acidemia. Pharmacol Ther. 2023;249:108501. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108501.","journal-title":"Pharmacol Ther"},{"key":"4522_CR3","unstructured":"Fenton WA, Gravel RA, Rosenblatt DS. Disorders of propionate and methylmalonate metabolism. In: The metabolic and molecular bases of inherited disease. 8th ed. 2001. p. 2165\u201393."},{"key":"4522_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-014-0130-8","volume":"9","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner MR, H\u00f6rster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. https:\/\/doi.org\/10.1186\/s13023-014-0130-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"4522_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ymgme.2017.07.003","volume":"122","author":"N Longo","year":"2017","unstructured":"Longo N, Price LB, Gappmaier E, et al. Anaplerotic therapy in propionic acidemia. Mol Genet Metab. 2017;122(1\u20132):51\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.003.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"4522_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/archneurol.2009.333","volume":"67","author":"FD Testai","year":"2010","unstructured":"Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol. 2010;67(2):148\u201353. https:\/\/doi.org\/10.1001\/archneurol.2009.333.","journal-title":"Arch Neurol"},{"issue":"6","key":"4522_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","volume":"28","author":"JL Fraser","year":"2016","unstructured":"Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016;28(6):682\u201393. https:\/\/doi.org\/10.1097\/MOP.0000000000000422.","journal-title":"Curr Opin Pediatr"},{"key":"4522_CR8","unstructured":"European Medicines Agency. Carbaglu (carglumic acid): summary of product characteristics [Internet]. 2025 [updated 09 Dec 2025]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carbaglu-epar-product-information_en.pdf. Accessed 2026 Feb 24."},{"issue":"1","key":"4522_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13023-018-0840-4","volume":"13","author":"A Chakrapani","year":"2018","unstructured":"Chakrapani A, Valayannopoulos V, Segarra NG, et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias. Orphanet J Rare Dis. 2018;13(1):97. https:\/\/doi.org\/10.1186\/s13023-018-0840-4.","journal-title":"Orphanet J Rare Dis"},{"key":"4522_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-016-0406-2","volume":"11","author":"V Valayannopoulos","year":"2016","unstructured":"Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J Rare Dis. 2016;11:32. https:\/\/doi.org\/10.1186\/s13023-016-0406-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"4522_CR11","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00467-014-2847-y","volume":"29","author":"ZK Zsengell\u00e9r","year":"2014","unstructured":"Zsengell\u00e9r ZK, Aljinovic N, Teot LA, et al. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol. 2014;29(11):2139\u201346. https:\/\/doi.org\/10.1007\/s00467-014-2847-y.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"4522_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000443630","volume":"109","author":"S Yap","year":"2016","unstructured":"Yap S, Leong HY, Abdul Aziz F, et al. N-Carbamylglutamate Is an Effective Treatment for Acute Neonatal Hyperammonaemia in a Patient with Methylmalonic Aciduria. Neonatology. 2016;109(4):303\u20137. https:\/\/doi.org\/10.1159\/000443630.","journal-title":"Neonatology"},{"key":"4522_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/IJGM.S10490","volume":"4","author":"M Daniotti","year":"2011","unstructured":"Daniotti M, la Marca G, Fiorini P, et al. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med. 2011;4:21\u20138. https:\/\/doi.org\/10.2147\/IJGM.S10490.","journal-title":"Int J Gen Med"},{"issue":"3","key":"4522_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000255168","volume":"97","author":"L Filippi","year":"2010","unstructured":"Filippi L, Gozzini E, Fiorini P, et al. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology. 2010;97(3):286\u201390. https:\/\/doi.org\/10.1159\/000255168.","journal-title":"Neonatology"},{"issue":"2","key":"4522_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10545-005-5260-7","volume":"28","author":"B Gebhardt","year":"2005","unstructured":"Gebhardt B, Dittrich S, Parbel S, et al. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis. 2005;28(2):241\u20134. https:\/\/doi.org\/10.1007\/s10545-005-5260-7.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"4522_CR16","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1007\/s12325-020-01305-1","volume":"37","author":"S Yap","year":"2020","unstructured":"Yap S, Vara R, Morais A. Post-transplantation Outcomes in Patients with PA or MMA: A Review of the Literature. Adv Ther. 2020;37(5):1866\u201396. https:\/\/doi.org\/10.1007\/s12325-020-01305-1.","journal-title":"Adv Ther"},{"issue":"3","key":"4522_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/jimd.12613","volume":"46","author":"A Chakrapani","year":"2023","unstructured":"Chakrapani A, Stojanovic J, Vara R, et al. Safety, efficacy, and timing of transplantation(s) in propionic and methylmalonic aciduria. J Inherit Metab Dis. 2023;46(3):466\u201381. https:\/\/doi.org\/10.1002\/jimd.12613.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"4522_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/jimd.12318","volume":"44","author":"F Molema","year":"2021","unstructured":"Molema F, Martinelli D, H\u00f6rster F, et al. Liver and\/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: An overview on European data. J Inherit Metab Dis. 2021;44(3):593\u2013605. https:\/\/doi.org\/10.1002\/jimd.12318.","journal-title":"J Inherit Metab Dis"},{"key":"4522_CR19","doi-asserted-by":"publisher","first-page":"101093","DOI":"10.1016\/j.ymgmr.2024.101093","volume":"40","author":"T Zelei","year":"2024","unstructured":"Zelei T, Vok\u00f3 Z, N\u00e9meth B, et al. Survival of propionic acidemia patients with liver transplant. Mol Genet Metab Rep. 2024;40:101093. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101093.","journal-title":"Mol Genet Metab Rep"},{"key":"4522_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ymgmr.2016.06.007","volume":"8","author":"A Burlina","year":"2016","unstructured":"Burlina A, Cazzorla C, Zanonato E, et al. Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria. Mol Genet Metab Rep. 2016;8:34\u201340. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.06.007.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4522_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13256-018-1631-1","volume":"12","author":"A Tummolo","year":"2018","unstructured":"Tummolo A, Melpignano L, Carella A, et al. Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report. J Med Case Rep. 2018;12(1):103. https:\/\/doi.org\/10.1186\/s13256-018-1631-1.","journal-title":"J Med Case Rep"},{"key":"4522_CR22","doi-asserted-by":"publisher","first-page":"4709548","DOI":"10.1155\/2020\/4709548","volume":"2020","author":"J Kido","year":"2020","unstructured":"Kido J, Matsumoto S, Nakamura K. Carglumic Acid Contributes to a Favorable Clinical Course in a Case of Severe Propionic Acidemia. Case Rep Pediatr. 2020;2020:4709548. https:\/\/doi.org\/10.1155\/2020\/4709548.","journal-title":"Case Rep Pediatr"},{"key":"4522_CR23","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.ymgmr.2021.100715","volume":"26","author":"E Kiykim","year":"2021","unstructured":"Kiykim E, Oguz O, Duman C, et al. Long-term N-carbamylglutamate treatment of hyperammonemia in patients with classic organic acidemias. Mol Genet Metab Rep. 2021;26:100715. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100715.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"4522_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13023-021-02032-8","volume":"16","author":"M Alfadhel","year":"2021","unstructured":"Alfadhel M, Nashabat M, Saleh M, et al. Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial. Orphanet J Rare Dis. 2021;16(1):422. https:\/\/doi.org\/10.1186\/s13023-021-02032-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"4522_CR25","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.26355\/eurrev_202207_29302","volume":"26","author":"A Burlina","year":"2022","unstructured":"Burlina A, Bettocchi I, Biasucci G, et al. Long-term use of carglumic acid in methylmalonic aciduria, propionic aciduria and isovaleric aciduria in Italy: a qualitative survey. Eur Rev Med Pharmacol Sci. 2022;26(14):5136\u201343. https:\/\/doi.org\/10.26355\/eurrev_202207_29302.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"4522_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40268-023-00449-z","volume":"24","author":"S Yap","year":"2024","unstructured":"Yap S, Lamireau D, Feillet F, et al. Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study. Drugs R D. 2024;24(1):69\u201380. https:\/\/doi.org\/10.1007\/s40268-023-00449-z.","journal-title":"Drugs R D"},{"issue":"1","key":"4522_CR27","doi-asserted-by":"publisher","first-page":"e2073","DOI":"10.1002\/mgg3.2073","volume":"11","author":"F Tubili","year":"2023","unstructured":"Tubili F, Pochiero F, Curcio MR, et al. Management of methylmalonic acidemia (MMA) with N-carbamylglutamate: A case report from Italy. Mol Genet Genomic Med. 2023;11(1):e2073. https:\/\/doi.org\/10.1002\/mgg3.2073.","journal-title":"Mol Genet Genomic Med"},{"issue":"9","key":"4522_CR28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/s10038-019-0614-4","volume":"64","author":"S Matsumoto","year":"2019","unstructured":"Matsumoto S, H\u00e4berle J, Kido J, et al. Urea cycle disorders-update. J Hum Genet. 2019;64(9):833\u201347. https:\/\/doi.org\/10.1038\/s10038-019-0614-4.","journal-title":"J Hum Genet"},{"key":"4522_CR29","unstructured":"Centers for Disease Control and Prevention. CDC growth charts data files with LMS values [Internet]. CDC; [updated 2 Sep 2024]. Available from: https:\/\/www.cdc.gov\/growthcharts\/cdc-data-files.htm. Accessed 2026 Feb 24."},{"issue":"9","key":"4522_CR30","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1177\/0883073813495959","volume":"28","author":"EF Augustine","year":"2013","unstructured":"Augustine EF, Adams HR, Mink JW. Clinical trials in rare disease: challenges and opportunities. J Child Neurol. 2013;28(9):1142\u201350. https:\/\/doi.org\/10.1177\/0883073813495959.","journal-title":"J Child Neurol"},{"issue":"3\u20134","key":"4522_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/TRD-180031","volume":"3","author":"N Ah Mew","year":"2018","unstructured":"Ah Mew N, Cnaan A, McCarter R, et al. Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: Lessons from the N-Carbamylglutamate Consortium. Transl Sci Rare Dis. 2018;3(3\u20134):157\u201370. https:\/\/doi.org\/10.3233\/TRD-180031.","journal-title":"Transl Sci Rare Dis"},{"issue":"3","key":"4522_CR32","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.ymgme.2023.107612","volume":"139","author":"J Vockley","year":"2023","unstructured":"Vockley J, Burton B, Jurecka A, et al. Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. Mol Genet Metab. 2023;139(3):107612. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107612.","journal-title":"Mol Genet Metab"},{"key":"4522_CR33","doi-asserted-by":"publisher","unstructured":"Ahmed MA, AbuAsal B, Barrett JS, et al. Unlocking the mysteries of rare disease drug development: A beginner's guide for clinical pharmacologists. Clin Transl Sci. 2025;18(4):e70215. https:\/\/doi.org\/10.1111\/cts.70215.","DOI":"10.1111\/cts.70215"},{"key":"4522_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.addr.2015.04.009","volume":"90","author":"S Matoori","year":"2015","unstructured":"Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev. 2015;90:55\u201368. https:\/\/doi.org\/10.1016\/j.addr.2015.04.009.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"4522_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41581-020-0267-8","volume":"16","author":"R Raina","year":"2020","unstructured":"Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. Nat Rev Nephrol. 2020;16(8):471\u201382. https:\/\/doi.org\/10.1038\/s41581-020-0267-8.","journal-title":"Nat Rev Nephrol"},{"key":"4522_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/HMER.S140711","volume":"10","author":"N Savy","year":"2018","unstructured":"Savy N, Brossier D, Brunel-Guitton C. Acute pediatric hyperammonemia: current diagnosis and management strategies. Hepat Med. 2018;10:105\u201315. https:\/\/doi.org\/10.2147\/HMER.S140711.","journal-title":"Hepat Med"},{"issue":"1","key":"4522_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainresrev.2007.06.026","volume":"56","author":"L Cagnon","year":"2007","unstructured":"Cagnon L, Braissant O. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res Rev. 2007;56(1):183\u201397. https:\/\/doi.org\/10.1016\/j.brainresrev.2007.06.026.","journal-title":"Brain Res Rev"},{"issue":"4","key":"4522_CR38","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10545-012-9546-2","volume":"36","author":"O Braissant","year":"2013","unstructured":"Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013;36(4):595\u2013612. https:\/\/doi.org\/10.1007\/s10545-012-9546-2.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"4522_CR39","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11011-020-00549-8","volume":"35","author":"A Sepehrinezhad","year":"2020","unstructured":"Sepehrinezhad A, Zarifkar A, Namvar G, et al. Astrocyte swelling in hepatic encephalopathy: molecular perspective of cytotoxic edema. Metab Brain Dis. 2020;35(4):559\u201378. https:\/\/doi.org\/10.1007\/s11011-020-00549-8.","journal-title":"Metab Brain Dis"},{"issue":"3\u20134","key":"4522_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11011-007-9067-0","volume":"22","author":"M Llansola","year":"2007","unstructured":"Llansola M, Rodrigo R, Monfort P, et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis. 2007;22(3\u20134):321\u201335. https:\/\/doi.org\/10.1007\/s11011-007-9067-0.","journal-title":"Metab Brain Dis"},{"key":"4522_CR41","unstructured":"Ali R, Nagalli S. Hyperammonemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: National Center for Biotechnology Information (US). Bookshelf ID: NBK557504. PMID: 32491436."},{"issue":"1","key":"4522_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13023-018-0963-7","volume":"13","author":"J H\u00e4berle","year":"2018","unstructured":"H\u00e4berle J, Chakrapani A, Ah Mew N, et al. Hyperammonaemia in classic organic acidaemias: a review of the literature and two case histories. Orphanet J Rare Dis. 2018;13(1):219. https:\/\/doi.org\/10.1186\/s13023-018-0963-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"4522_CR43","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/s41390-023-02722-y","volume":"94","author":"U Lichter-Konecki","year":"2023","unstructured":"Lichter-Konecki U, Sanz JH, Urea Cycle Disorders Consortium. Relationship between longitudinal changes in neuropsychological outcome and disease biomarkers in urea cycle disorders. Pediatr Res. 2023;94(6):2005\u201315. https:\/\/doi.org\/10.1038\/s41390-023-02722-y.","journal-title":"Pediatr Res"},{"issue":"2","key":"4522_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1056\/NEJMp1212324","volume":"368","author":"HM Krumholz","year":"2013","unstructured":"Krumholz HM. Post-hospital syndrome\u2013an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100\u20132. https:\/\/doi.org\/10.1056\/NEJMp1212324.","journal-title":"N Engl J Med"},{"key":"4522_CR45","unstructured":"Wilsdon T, Axelsen K, Jayasuriya R, et al. The economic cost of living with a rare disease across Europe [Internet]. 2024. Available from: https:\/\/media.crai.com\/wp-content\/uploads\/2024\/10\/28114611\/CRA-Alexion-Quantifying-the-Burden-of-RD-in-Europe-Full-report-October2024.pdf. Accessed 23 Feb 2026."},{"issue":"1","key":"4522_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jmd2.12234","volume":"61","author":"H Saleemani","year":"2021","unstructured":"Saleemani H, Egri C, Horvath G, et al. Dietary management and growth outcomes in children with propionic acidemia: A natural history study. JIMD Rep. 2021;61(1):67\u201375. https:\/\/doi.org\/10.1002\/jmd2.12234.","journal-title":"JIMD Rep"},{"issue":"4","key":"4522_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ymgme.2019.02.003","volume":"126","author":"F Molema","year":"2019","unstructured":"Molema F, Gleich F, Burgard P, et al. Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment. Mol Genet Metab. 2019;126(4):397\u2013405. https:\/\/doi.org\/10.1016\/j.ymgme.2019.02.003.","journal-title":"Mol Genet Metab"},{"key":"4522_CR48","doi-asserted-by":"publisher","unstructured":"Forny P, H\u00f6rster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44(3):566\u2013592. https:\/\/doi.org\/10.1002\/jimd.12370. Epub 2021 Mar 9. Erratum in: J Inherit Metab Dis. 2022 Jul;45(4):862. doi: 10.1002\/jimd.12535.","DOI":"10.1002\/jimd.12370"},{"issue":"2","key":"4522_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1515\/jpem.2004.17.2.239","volume":"17","author":"M Al-Owain","year":"2004","unstructured":"Al-Owain M, Freehauf C, Bernstein L, et al. Growth hormone deficiency associated with methylmalonic acidemia. J Pediatr Endocrinol Metab. 2004;17(2):239\u201343. https:\/\/doi.org\/10.1515\/jpem.2004.17.2.239.","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04522-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04522-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:02Z","timestamp":1791285422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04522-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4522"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04522-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study is conducted in accordance with the ethical standards of the institutional and\/or national research committees at each centre and with the 1964 Declaration of Helsinki, as revised in 2013. Ethics approval was managed locally, the study protocol was approved by the local institutional review board at each study site which includes: North West - Liverpool Central Research Ethics Committee (Primary Investigator initiator centre); Ethics Committee for Clinical Trials of the Province of Padua; Research Ethics Committee at Universitario y Polit\u00e9cnico La Fe (subsequently also approved by The Management of Ram\u00f3n y Cajal University Hospital); Ethics Committee of the University of Naples Federico II; Independent Ethics Committee of the A.O.U. Consorziale Policlinico of Bari (study subsequently authorised by Milano Area 2 Ethics Committee); Research Ethics Committee of the Balearic Islands (study subsequently authorised by Directorate General of Inspection and Regulation, Community of Madrid and also Ethics Committee of Hospital Universitario La Paz \/ Hospital Carlos III \/ Hospital Cantoblanco); Advisory Committee on Post-Authorisation Studies with Medicinal Products (CAEPM), Directorate General for Health Planning and Regulation, Government of Catalonia; Regional Ethics Committee for Clinical Research of the Tuscany Region \u2013 Pediatric Ethics Committee Section. Prior to inclusion, written informed consent has been provided by all participants or caregivers as appropriate.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The informed consent form grants permission for the use of anonymized data for scientific publication purposes.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Vincenzo Giordano, Zahir Boutoub and Thibault Delcroix are employees of Recordati Rare Diseases the company funding the study and article processing fees.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"348"}}